MRD status at randomization and degree of MRD positivity as a percentage of leukemic cells in bone marrow aspirates
| Group . | N . | MRD− (<0.1%) . | MRD+ (≥0.1%) . | Degree of MRD positivity . | ||
|---|---|---|---|---|---|---|
| 0.1-0.5% . | ≥0.5-1.0% . | >1.0% . | ||||
| n (%) . | ||||||
| All patients | 463 | 244 (53) | 219 (47) | 132 (29) | 36 (8) | 51 (11) |
| Oral azacitidine | 236 | 133 (56) | 103 (44) | 63 (27) | 16 (7) | 24 (10) |
| Placebo | 227 | 111 (49) | 116 (51) | 69 (30) | 20 (9) | 27 (12) |
| Group . | N . | MRD− (<0.1%) . | MRD+ (≥0.1%) . | Degree of MRD positivity . | ||
|---|---|---|---|---|---|---|
| 0.1-0.5% . | ≥0.5-1.0% . | >1.0% . | ||||
| n (%) . | ||||||
| All patients | 463 | 244 (53) | 219 (47) | 132 (29) | 36 (8) | 51 (11) |
| Oral azacitidine | 236 | 133 (56) | 103 (44) | 63 (27) | 16 (7) | 24 (10) |
| Placebo | 227 | 111 (49) | 116 (51) | 69 (30) | 20 (9) | 27 (12) |
MRD, measurable residual disease.